A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)


About this study

The purpose of this study is to assess the effectiveness and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing, when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of up to 15 days and an 18-month Double-Masked Treatment Period.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Male or female diagnosed with FECD.

Exclusion Criteria:

- Females who are pregnant or lactating.

- Any ocular surgery for FECD (e.g., penetrating keratoplasty (PKP), Descemet stripping
endothelial keratoplasty (DSEK), Descemet membrane endothelial keratoplasty (DMEK),
Descemet stripping automated endothelial keratoplasty (DSAEK), Descemet stripping only
(DSO) in the study eye.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Keith Baratz, M.D.

Open for enrollment

Contact information:

Emily Treichel

(507) 284-8558


More information


Publications are currently not available